Clinical trials: Liraglutide
Obesity, Overweight
In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database
This study is conducted in Europe. The aim of this study is to investigate the usage of liraglutide for weight management in clinical practice using the CPRD (Clinical Practice Research Datalink) primary care database.
- Trial name
- NCT03479762
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 105 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe and South America. This trial is designed to show the effect of treatment with liraglutide added to existing glimepiride and metformin combination therapy and to compare it with the…
- Trial name
- LEAD-5 (NCT00331851)
- Testing
- liraglutide, insulin glargine, metformin
- Where
- 116 sites in Argentina, Austria and 16 more
- Volunteers
- 584 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
This study is conducted in the United States of America (USA). The aim of the study is to monitor the number of annual new adult cases of medullary thyroid carcinoma (MTC) and to establish a registry for these new cases in order…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma, Weight Management
- Trial name
- NCT01511393
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 6,750 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Healthy
Comparison of Three Liraglutide Formulations in Healthy Volunteers
This trial is conducted in Oceania. The aim of this trial is to test for bioequivalence between each of the two new liraglutide formulations at pH 7.9 and 8.15 and the planned Phase 3 formulation at pH 7.7.
- Trial name
- NCT01514487
- Testing
- liraglutide
- Where
- Australia
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of the trial is to investigate the efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes…
- Trial name
- DUAL™ III (NCT01676116)
- Testing
- insulin degludec/liraglutide, liraglutide, exenatide
- Where
- 109 sites in United States, Australia and 3 more
- Volunteers
- 438 people
- Sponsor
- Novo Nordisk A/S
Type2 Diabetes, Coronary Artery Disease
Liraglutide Effects on Epicardial Fat Inflammatory Genes
Epicardial adipose tissue (EAT) is the visceral fat of the heart. EAT could locally affect the coronary arteries through local secretion of pro-inflammatory cytokines.
- Trial name
- NCT03260881
- Testing
- Liraglutide Pen Injector [Victoza]
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Miami
T2DM
Comprehensive Clinical Evaluation Study of GLP-1RA
The objective of this project is to identify the most efficacious glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of adult patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT06686134
- Where
- China
- Volunteers
- 492 people
- Sponsor
- LI YAN
Diabetes Mellitus, Type 2
Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure
Primary objective: To demonstrate the superiority of insulin glargine over liraglutide in terms of percentage of patients reaching a Glycosylated Haemoglobin (HbA1c) < 7% at the end of the comparative period (24 weeks) in Type 2…
- Trial name
- EAGLE (NCT01117350)
- Testing
- Insulin glargine, Liraglutide, Metformin
- Where
- 136 sites in United States, Austria and 15 more
- Volunteers
- 978 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2, Diabetes
The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study
The aim of this clinical trial is to assess and compare the effect of insulin detemir in combination with liraglutide and metformin versus insulin detemir in combination with insulin aspart and metformin in subjects with very…
- Trial name
- SIMPLE (NCT01966978)
- Testing
- Metformin, Detemir, Liraglutide
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
This trial is conducted in Asia. The aim of this trial is to confirm the superiority of insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus after 26…
- Trial name
- DUAL™ II China (NCT03175120)
- Testing
- Insulin degludec/liraglutide, Insulin degludec
- Where
- 37 sites in China, Hong Kong
- Volunteers
- 453 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes
This trial is conducted in Africa and Asia. The aim of the trial is to investigate the efficacy and safety of liraglutide versus sulphonylurea (SU) both in combination with metformin during Ramadan in subjects with type 2…
- Trial name
- LIRA-Ramadan™ (NCT01917656)
- Testing
- liraglutide, metformin, sulphonylurea
- Where
- 41 sites in Algeria, India and 5 more
- Volunteers
- 343 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Mild Cognitive Impairment
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
This is an investigator-led prospective, randomized, open label, parallel study to explore and evaluate the therapeutic effects of Liraglutide, Empagliflozin and Linagliptin on the cognitive function in T2DM patients with mild…
- Trial name
- LIGHT-MCI (NCT05313529)
- Testing
- Liraglutide, Empagliflozin, Linagliptin
- Where
- 5 sites in China
- Volunteers
- 396 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Diabetes, Diabetes Mellitus, Type 2
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of insulin degludec/liraglutide in insulin naïve subjects inadequately controlled…
- Trial name
- DUAL™IV (NCT01618162)
- Testing
- insulin degludec/liraglutide
- Where
- 87 sites in United States, Bulgaria and 6 more
- Volunteers
- 435 people
- Sponsor
- Novo Nordisk A/S
Diabete Type 2
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
This is a phase Ib/IIa, single ascending dose study of the safety, tolerability and preliminary efficacy of sublingual (SL) Liraglutide in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT05268237
- Testing
- Liraglutide
- Where
- Hong Kong
- Volunteers
- 15 people
- Sponsor
- Biolingus
Childhood Obesity, Treatment Adherence
The Evira Study: Additional Support During Obesity Treatment
The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with obesity medication in adolescents with obesity.
- Trial name
- NCT06836284
- Testing
- Digi-physical treatment tool, Evira, Obesity medication with liraglutide or semaglutide
- Where
- 3 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska Institutet
Diabetes Mellitus, Type 2
A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes
The aim of this trial is to evaluate the safety of single doses of a study drug known as LY3325656 that is given orally to healthy participants and participants with type 2 diabetes.
- Trial name
- NCT03115099
- Testing
- LY3325656, Liraglutide, Sitagliptin
- Where
- 2 sites in Singapore
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes
The majority of people with type 2 diabetes (T2D) are overweight, and while weight gain is a major contributor to diabetes, a minority of patients with T2D are not overweight or obese.
- Trial name
- Lean-DM (NCT04657939)
- Testing
- Liraglutide, Pioglitazone
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- University of Leeds
Diabetes, Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers
This trial is conducted in Japan. The aim of this trial is to assess the safety and tolerability of NNC 90-1170 (liraglutide) in healthy Japanese male subjects.
- Trial name
- NCT01620463
- Testing
- liraglutide
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Microvascular Angina
Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis
The aim of the present study is to evaluate the effect of treatment with Liraglutide on the coronary microvasculature and angina symptoms, in overweight patients with microvascular dysfunction and angina pectoris but no coronary…
- Trial name
- GAP (NCT02602600)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 33 people
- Sponsor
- Eva Prescott
Diabetes, Diabetes Mellitus Type 2
A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
This trial is conducted in the United States of America (USA). The aim of the trial is to investigate the efficacy, safety, and tolerability of once-daily subcutaneous (SC) injections of NNC0090-2746 for 12 weeks, as an adjunct…
- Trial name
- NCT02205528
- Testing
- Liraglutide, Metformin, NNC0090-2746
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Novo Nordisk A/S